newest glp 1 drug GLP-1 Drugs from the Gray Market Swiss Re says GLP-1 drugs

Compared to Novo Nordisks A/S NYSE: NVO Rybelsus, orforglipron appears to have multiple advantages

Furthermore, there is a persistent shortage of liraglutide, semaglutide injections, and dulaglutide

Additionally, even if it does stay more expensive than some other drugs, its also worth considering that its the kind of drug people are probably willing to pay a bit more for

Aim to drink regularly throughout the day, even if you're not craving water

These effects are seen even outside of diabetes control.[ref] Related article: APOE genotype and Alzheimers risk Cardiovascular disease benefits: A number of studies have shown that GLP-1 RAs provide benefits for reducing cardiovascular disease

As of early 2025, well over 30 new GLP-1 drugs are in development